The team will use the five-year funding to develop a liquid biopsy-based assay to select and prioritize liver cancer patients who need a liver transplant.
The team has begun analyzing additional analytes in HER2-positive breast cancer patients and will present preliminary results at AACR's annual meeting in May.
Through a startup called FCS Technology, the team is hoping to market the platform for cancer research and, eventually, clinical diagnostic applications.
Angle's Parsortix yielded lower white blood cell backgrounds in samples, but Biolidics' ClearCell detected melanoma CTCs in additional samples that Parsortix missed.
The team plans to develop an assay that integrates circulating tumor cells and DNA to eliminate the need for repeated imaging surveillance in stage III melanoma patients.
